Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Functional evidence implicating chromosome 7q22 haploinsufficiency in myelodysplastic syndrome pathogenesis.

Jasmine C Wong | Kelley M Weinfurtner | Maria Del Pilar Alzamora | Scott C Kogan | Michael R Burgess | Yan Zhang | Joy Nakitandwe | Jing Ma | Jinjun Cheng | Shann-Ching Chen | Theodore T Ho | Johanna Flach | Damien Reynaud | Emmanuelle Passegué | James R Downing | Kevin Shannon
eLife | 2015

Chromosome 7 deletions are highly prevalent in myelodysplastic syndrome (MDS) and likely contribute to aberrant growth through haploinsufficiency. We generated mice with a heterozygous germ line deletion of a 2-Mb interval of chromosome band 5A3 syntenic to a commonly deleted segment of human 7q22 and show that mutant hematopoietic cells exhibit cardinal features of MDS. Specifically, the long-term hematopoietic stem cell (HSC) compartment is expanded in 5A3(+/del) mice, and the distribution of myeloid progenitors is altered. 5A3(+/del) HSCs are defective for lymphoid repopulating potential and show a myeloid lineage output bias. These cell autonomous abnormalities are exacerbated by physiologic aging and upon serial transplantation. The 5A3 deletion partially rescues defective repopulation in Gata2 mutant mice. 5A3(+/del) hematopoietic cells exhibit decreased expression of oxidative phosphorylation genes, increased levels of reactive oxygen species, and perturbed oxygen consumption. These studies provide the first functional data linking 7q22 deletions to MDS pathogenesis.

Pubmed ID: 26193121

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NHLBI NIH HHS, United States
    Id: R01 HL092471
  • Agency: NCI NIH HHS, United States
    Id: P01 CA040046
  • Agency: NCI NIH HHS, United States
    Id: U01 CA084221
  • Agency: NCI NIH HHS, United States
    Id: R37 CA72614
  • Agency: NIGMS NIH HHS, United States
    Id: T32 GM008284
  • Agency: NIBIB NIH HHS, United States
    Id: T32 EB009383
  • Agency: NCI NIH HHS, United States
    Id: P30 CA021765
  • Agency: NCI NIH HHS, United States
    Id: R37 CA072614
  • Agency: NCI NIH HHS, United States
    Id: T32 CA108462
  • Agency: NCI NIH HHS, United States
    Id: P01 CA40046

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


BioLegend (tool)

RRID:SCR_001134

Commercial antibody supplier and developer for biomedical research. These products are compatible with use in flow cytometry and mass cytometry, immunoprecipitation and chip, western blotting, immunofluorescence microscopy, and quantitative multiplexing.

View all literature mentions

LIMMA (tool)

RRID:SCR_010943

Software package for the analysis of gene expression microarray data, especially the use of linear models for analyzing designed experiments and the assessment of differential expression.

View all literature mentions

C57BL/6J (tool)

RRID:IMSR_JAX:000664

Mus musculus with name C57BL/6J from IMSR.

View all literature mentions